Pacific Biosciences of California, Inc.
PACBFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
154
Cost of Revenue
117
Gross Profit
37
Gross Margin
24.2%
Operating Income
-474
Operating Margin
-308.0%
Net Income
-310
Net Margin
-201.2%
EPS (Basic)
$-1.13
EPS (Diluted)
$-1.07
EBITDA
-243
EBITDA Margin
-157.6%
2023
12/31/2023
Revenue
201
Cost of Revenue
148
Gross Profit
53
Gross Margin
26.3%
Operating Income
-334
Operating Margin
-166.8%
Net Income
-307
Net Margin
-153.0%
EPS (Basic)
$-1.21
EPS (Diluted)
$-1.21
EBITDA
-271
EBITDA Margin
-135.2%
2022
12/31/2022
Revenue
128
Cost of Revenue
79
Gross Profit
49
Gross Margin
38.2%
Operating Income
-307
Operating Margin
-239.4%
Net Income
-314
Net Margin
-244.9%
EPS (Basic)
$-1.40
EPS (Diluted)
$-1.40
EBITDA
-282
EBITDA Margin
-220.0%
2021
12/31/2021
Revenue
131
Cost of Revenue
72
Gross Profit
59
Gross Margin
45.1%
Operating Income
-210
Operating Margin
-161.2%
Net Income
-181
Net Margin
-138.9%
EPS (Basic)
$-0.89
EPS (Diluted)
$-0.89
EBITDA
-251
EBITDA Margin
-192.1%
2020
12/31/2020
Revenue
79
Cost of Revenue
46
Gross Profit
33
Gross Margin
41.3%
Operating Income
-104
Operating Margin
-132.3%
Net Income
29
Net Margin
37.3%
EPS (Basic)
$0.18
EPS (Diluted)
$0.17
EBITDA
39
EBITDA Margin
49.4%